NASDAQ:ELDN Eledon Pharmaceuticals (ELDN) Stock Price, News & Analysis $3.80 +0.01 (+0.13%) As of 12:31 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Eledon Pharmaceuticals Stock (NASDAQ:ELDN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Eledon Pharmaceuticals alerts:Sign Up Key Stats Today's Range$3.67▼$3.8650-Day Range$2.42▼$4.1452-Week Range$1.35▼$4.60Volume626,570 shsAverage Volume1.19 million shsMarket Capitalization$293.71 millionP/E RatioN/ADividend YieldN/APrice Target$9.67Consensus RatingHold Company Overview Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of therapies for diseases characterized by smooth muscle dysfunction. The company leverages a proprietary ion-channel modulation platform to identify and optimize small-molecule compounds that can either restore or inhibit smooth muscle activity, with the goal of addressing gastrointestinal, hepatic and cardiovascular disorders. Eledon’s pipeline comprises several preclinical and early-phase clinical programs targeting high-unmet-need indications. Its lead candidate has advanced into initial human trials, and additional assets are in IND-enabling studies. To support development, the company collaborates with academic research institutions and specialty contract development organizations, drawing on external expertise for pharmacology, toxicology and clinical trial execution. Based in the United States with operations in Europe, Eledon Pharmaceuticals conducts multi-center studies across North America and the EMEA region. The company’s leadership team brings together experienced drug development professionals, clinical operations specialists and regulatory experts, positioning Eledon to advance its portfolio toward late-stage trials and eventual commercialization. AI Generated. May Contain Errors. Read More Eledon Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks25th Percentile Overall ScoreELDN MarketRank™: Eledon Pharmaceuticals scored higher than 25% of companies evaluated by MarketBeat, and ranked 742nd out of 857 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingEledon Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialEledon Pharmaceuticals has a consensus price target of $9.67, representing about 157.4% upside from its current price of $3.76.Amount of Analyst CoverageEledon Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Eledon Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Eledon Pharmaceuticals is -7.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Eledon Pharmaceuticals is -7.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEledon Pharmaceuticals has a P/B Ratio of 2.78. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Eledon Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.74% of the float of Eledon Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEledon Pharmaceuticals has a short interest ratio ("days to cover") of 6.21.Change versus previous monthShort interest in Eledon Pharmaceuticals has recently increased by 8.60%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEledon Pharmaceuticals does not currently pay a dividend.Dividend GrowthEledon Pharmaceuticals does not have a long track record of dividend growth. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Eledon Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest16 people have searched for ELDN on MarketBeat in the last 30 days. This is an increase of 433% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Eledon Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Eledon Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders12.30% of the stock of Eledon Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions56.77% of the stock of Eledon Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Eledon Pharmaceuticals' insider trading history. Receive ELDN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eledon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ELDN Stock News HeadlinesNewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon ...April 30, 2026 | markets.businessinsider.comHere is Why Eledon Pharmaceuticals (ELDN) is an Unstoppable Stock That Could Double Your MoneyApril 20, 2026 | finance.yahoo.com$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s known for playing his cards “close to the vest”… Is going to give you the name and ticker symbol of a company he believes will skyrocket thanks to the coming Starlink IPO…May 7 at 1:00 AM | Paradigm Press (Ad)Eledon Pharmaceuticals, Inc. Common Stock (ELDN)March 27, 2026 | nasdaq.comEledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial ResultsMarch 20, 2026 | finanznachrichten.deEledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial ResultsMarch 19, 2026 | globenewswire.comEledon Pharmaceuticals: Tegoprubart Continues To Shine As Immunosuppressive AlternativeMarch 16, 2026 | seekingalpha.comEledon Pharmaceuticals, Inc.: Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago MedicineMarch 16, 2026 | finanznachrichten.deSee More Headlines ELDN Stock Analysis - Frequently Asked Questions How have ELDN shares performed this year? Eledon Pharmaceuticals' stock was trading at $1.51 at the beginning of 2026. Since then, ELDN stock has increased by 148.7% and is now trading at $3.7550. How were Eledon Pharmaceuticals' earnings last quarter? Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) released its quarterly earnings data on Thursday, March, 19th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.10. When did Eledon Pharmaceuticals IPO? Eledon Pharmaceuticals (ELDN) raised $91 million in an initial public offering on Wednesday, September 17th 2014. The company issued 6,480,000 shares at a price of $13.00-$15.00 per share. Who are Eledon Pharmaceuticals' major shareholders? Top institutional investors of Eledon Pharmaceuticals include SG Americas Securities LLC (0.84%), Bank of New York Mellon Corp (0.19%), Mitchell & Pahl Private Wealth LLC (0.04%) and Kestra Private Wealth Services LLC (0.03%). View institutional ownership trends. How do I buy shares of Eledon Pharmaceuticals? Shares of ELDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Eledon Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Eledon Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Arista Networks (ANET), ServiceNow (NOW), Adobe (ADBE) and CrowdStrike (CRWD). Company Calendar Last Earnings3/19/2026Today5/07/2026Next Earnings (Estimated)5/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 ELDN's financial health is in the Green zone, according to TradeSmith. ELDN has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ELDN CIK1404281 Webnovustherapeutics.com Phone(949) 238-8090FaxN/AEmployees10Year Founded2004Price Target and Rating Average Price Target for Eledon Pharmaceuticals$9.67 High Price Target$12.00 Low Price Target$8.00 Potential Upside/Downside+154.7%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$45.62 million Net MarginsN/A Pretax MarginN/A Return on Equity-85.61% Return on Assets-31.93% Debt Debt-to-Equity RatioN/A Current Ratio7.40 Quick Ratio7.40 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.35 per share Price / Book2.81Miscellaneous Outstanding Shares77,190,000Free Float67,694,000Market Cap$292.94 million OptionableOptionable Beta0.94 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:ELDN) was last updated on 5/7/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredThe $1.75T "Backdoor" ticker (NOT Starlink)When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...Behind the Markets | SponsoredSell 99% of Your Stocks, Do THIS Instead…Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...The Oxford Club | SponsoredTrade this between 9:30 and 10:45 am ESTThe first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...Base Camp Trading | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eledon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eledon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
